Skip to main content
Top
Published in: The International Journal of Cardiovascular Imaging 4/2018

01-04-2018 | Original Paper

CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase

Authors: Sainan Cheng, Yeon Hyeon Choe, Hideki Ota, Chen Cui, Gang Yin, Minjie Lu, Lu Li, Xiuyu Chen, Sanjay K. Prasad, Shihua Zhao

Published in: The International Journal of Cardiovascular Imaging | Issue 4/2018

Login to get access

Abstract

End-stage phase of hypertrophic cardiomyopathy (ES-HCM) is a recognized part of HCM disease spectrum. Information on cardiac magnetic resonance (CMR) studies for ES-HCM especially for those without ventricular remodeling has been limited. We aimed to evaluate the morpho-functional and tissue features of ES-HCM with or without ventricular remodeling and to explore CMR prognostic value in these patients. We analysed CMR scans of sixty-three ES-HCM patients and divided them into those with ventricular dilatation (D-ES, n = 41) and those with normal ventricular size (N-ES, n = 22). Cox proportional hazards models were used to assess the association between CMR parameters and outcomes. Patients in D-ES showed hypokinetic-dilated HCM phenotype, while patients in N-ES showed hypokinetic-restrictive HCM phenotype. LGE extent was significantly larger in D-ES (34.7% ± 15.4% vs. 22.8% ± 7.7%; P < 0.01). Atrial fibrillation and edema of lower extremity were more common in N-ES (72.7 vs. 29.3% and 54.5 vs. 24.4%, respectively; P < 0.05). Log-rank test found no significant difference between 2 groups in combined end point of cardiovascular events (χ2 = 0.66, P = 0.418). In multivariate analysis, LGE (HR 1.57–1.83 per 10% LGE increase, P < 0.01) and indexed left atrial volume (LAVI) (HR 1.14–1.21 per 20 mL/m2 increase, P < 0.05) remained independently associated with combined end point when adjusted by other risk factors. The CMR features of HCM in end-stage span between two extremes. LGE is more extensive in those with ventricular remodeling and LAVI is larger in those with normal ventricular size. Both LGE and LAVI are significant predictors of poor outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65:1249–1254CrossRefPubMed Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65:1249–1254CrossRefPubMed
2.
go back to reference Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C (1989) Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 320:749–755CrossRefPubMed Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C (1989) Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 320:749–755CrossRefPubMed
3.
go back to reference Funakoshi M, Imamura M, Sasaki J et al (1984) Seventeen year follow-up of a patient with hypertrophic cardiomyopathy which progressed to dilated cardiomyopathy. Jpn Heart J 25:805–809CrossRefPubMed Funakoshi M, Imamura M, Sasaki J et al (1984) Seventeen year follow-up of a patient with hypertrophic cardiomyopathy which progressed to dilated cardiomyopathy. Jpn Heart J 25:805–809CrossRefPubMed
4.
go back to reference Spirito P, Maron BJ (1987) Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 9:1013–1017CrossRefPubMed Spirito P, Maron BJ (1987) Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 9:1013–1017CrossRefPubMed
5.
go back to reference Hina K, Kusachi S, Iwasaki K et al (1993) Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value. Clin Cardiol 16:403–407CrossRefPubMed Hina K, Kusachi S, Iwasaki K et al (1993) Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value. Clin Cardiol 16:403–407CrossRefPubMed
6.
go back to reference Maron BJ, Spirito P (1998) Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81:1339–1344CrossRefPubMed Maron BJ, Spirito P (1998) Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81:1339–1344CrossRefPubMed
7.
go back to reference Thaman R, Gimeno JR, Murphy RT et al (2005) Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 91:920–925CrossRefPubMedPubMedCentral Thaman R, Gimeno JR, Murphy RT et al (2005) Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 91:920–925CrossRefPubMedPubMedCentral
8.
go back to reference Biagini E, Coccolo F, Ferlito M et al (2005) Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 46:1543–1550CrossRefPubMed Biagini E, Coccolo F, Ferlito M et al (2005) Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 46:1543–1550CrossRefPubMed
9.
go back to reference Harris KM, Spirito P, Maron MS et al (2006) Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114:216–225CrossRefPubMed Harris KM, Spirito P, Maron MS et al (2006) Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114:216–225CrossRefPubMed
10.
go back to reference Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H (2011) Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 17:459–464CrossRefPubMed Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H (2011) Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 17:459–464CrossRefPubMed
11.
12.
go back to reference Romano S, Jue J, White B, Farzaneh-Far A (2016) Evolution of hypertrophic cardiomyopathy assessed using serial cardiovascular magnetic resonance imaging. Int J Cardiol 216:156–158CrossRefPubMed Romano S, Jue J, White B, Farzaneh-Far A (2016) Evolution of hypertrophic cardiomyopathy assessed using serial cardiovascular magnetic resonance imaging. Int J Cardiol 216:156–158CrossRefPubMed
13.
go back to reference Matoh F, Satoh H, Shiraki K et al (2007) Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Card Fail 13:372–379CrossRefPubMed Matoh F, Satoh H, Shiraki K et al (2007) Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Card Fail 13:372–379CrossRefPubMed
14.
go back to reference Hamada T, Kubo T, Kitaoka H et al (2010) Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy. Clin Cardiol 33:E24-28CrossRef Hamada T, Kubo T, Kitaoka H et al (2010) Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy. Clin Cardiol 33:E24-28CrossRef
15.
go back to reference Goto D, Kinugawa S, Hamaguchi S et al (2013) Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy: report from the registry data in Japan. J Cardiol 61:65–70CrossRefPubMed Goto D, Kinugawa S, Hamaguchi S et al (2013) Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy: report from the registry data in Japan. J Cardiol 61:65–70CrossRefPubMed
16.
go back to reference Machii M, Satoh H, Shiraki K et al (2014) Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome. Magn Reson Imaging 32:118–124CrossRefPubMed Machii M, Satoh H, Shiraki K et al (2014) Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome. Magn Reson Imaging 32:118–124CrossRefPubMed
17.
go back to reference American College of Cardiology Foundation Task Force on Expert Consensus Documents (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 55:2614–2662CrossRef American College of Cardiology Foundation Task Force on Expert Consensus Documents (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 55:2614–2662CrossRef
18.
go back to reference O’Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874CrossRefPubMed O’Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874CrossRefPubMed
19.
go back to reference Rubinshtein R, Glockner JF, Ommen SR et al (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3:51–58CrossRefPubMed Rubinshtein R, Glockner JF, Ommen SR et al (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3:51–58CrossRefPubMed
20.
go back to reference Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495CrossRefPubMed Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495CrossRefPubMed
21.
go back to reference Weng Z, Yao J, Chan RH et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 9:1392–1402CrossRefPubMed Weng Z, Yao J, Chan RH et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 9:1392–1402CrossRefPubMed
22.
go back to reference Maron BJ, Maron MS (2016) LGE means better selection of HCM patients for primary prevention implantable defibrillators (editorial comment). JACC Cardiovasc Imaging 9:1403–1406CrossRefPubMed Maron BJ, Maron MS (2016) LGE means better selection of HCM patients for primary prevention implantable defibrillators (editorial comment). JACC Cardiovasc Imaging 9:1403–1406CrossRefPubMed
23.
go back to reference Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276CrossRefPubMed Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276CrossRefPubMed
24.
go back to reference Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed
25.
go back to reference Le TT, Tan RS, De Deyn M et al (2016) Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. J Cardiovasc Magn Reson 18:21CrossRefPubMedPubMedCentral Le TT, Tan RS, De Deyn M et al (2016) Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. J Cardiovasc Magn Reson 18:21CrossRefPubMedPubMedCentral
26.
go back to reference Schulz-Menger J, Bluemke DA, Bremerich J et al (2013) Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson 15(1):35CrossRefPubMedPubMedCentral Schulz-Menger J, Bluemke DA, Bremerich J et al (2013) Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson 15(1):35CrossRefPubMedPubMedCentral
27.
go back to reference Moravsky G, Ofek E, Rakowski H et al (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 6:587–596CrossRefPubMed Moravsky G, Ofek E, Rakowski H et al (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 6:587–596CrossRefPubMed
28.
go back to reference Cerqueira MD, Weissman NJ, Dilsizian V et al (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105:539–542CrossRefPubMed Cerqueira MD, Weissman NJ, Dilsizian V et al (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105:539–542CrossRefPubMed
29.
go back to reference Kubo T, Gimeno JR, Bahl A et al (2007) Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 49:2419–2426CrossRefPubMed Kubo T, Gimeno JR, Bahl A et al (2007) Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 49:2419–2426CrossRefPubMed
30.
go back to reference Biagini E, Spirito P, Rocchi G et al (2009) Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 104:1727–1731CrossRefPubMed Biagini E, Spirito P, Rocchi G et al (2009) Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 104:1727–1731CrossRefPubMed
31.
go back to reference Galati G, Leone O, Pasquale F et al (2016) Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study of 30 explanted hearts. Circ Heart Fail 9:e003090CrossRefPubMed Galati G, Leone O, Pasquale F et al (2016) Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study of 30 explanted hearts. Circ Heart Fail 9:e003090CrossRefPubMed
32.
go back to reference Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349:1027–1035CrossRefPubMed Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349:1027–1035CrossRefPubMed
33.
go back to reference Pinamonti B, Di Lenarda A, Nucifora G, Gregori D, Perkan A, Sinagra G (2008) Incremental prognostic value of restrictive filling pattern in hypertrophic cardiomyopathy: a Doppler echocardiographic study. Eur J Echocardiogr 9:466–471PubMed Pinamonti B, Di Lenarda A, Nucifora G, Gregori D, Perkan A, Sinagra G (2008) Incremental prognostic value of restrictive filling pattern in hypertrophic cardiomyopathy: a Doppler echocardiographic study. Eur J Echocardiogr 9:466–471PubMed
34.
go back to reference Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517–2524CrossRefPubMed Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517–2524CrossRefPubMed
Metadata
Title
CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase
Authors
Sainan Cheng
Yeon Hyeon Choe
Hideki Ota
Chen Cui
Gang Yin
Minjie Lu
Lu Li
Xiuyu Chen
Sanjay K. Prasad
Shihua Zhao
Publication date
01-04-2018
Publisher
Springer Netherlands
Published in
The International Journal of Cardiovascular Imaging / Issue 4/2018
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-017-1263-3

Other articles of this Issue 4/2018

The International Journal of Cardiovascular Imaging 4/2018 Go to the issue